Research in transplant immunology using non-human primate (NHP) species to evaluate immunologic strategies to prevent rejection and prolong allograft survival has yielded results that have translated successfully into human organ transplant patient management. Other therapies have not proceeded to human translation due to failure in NHP testing, arguably sparing humans the futility and risk of such testing. The NHP transplant models are ethically necessary for drug development in this field and provide the closest analogue to human transplant patients available. The refinement of this resource with respect to colony MHC typing, reagent and assay development, and availability to the research community has greatly enhanced knowledge about transplant immunology and drug development.
Bibliographical noteFunding Information:
This work was funded by NIH U19-AI131471-01, UO1-AI102463.
The National Institute of Allergy and Infectious Diseases (NIAID) and the NIH Office of Research Infrastructure Programs (ORIP) support the NHP Reagent Resource ( summarizes reagents available from the NHP Reagent Resource. http://www.nhpreagents.org/NHP/default.aspx ), which develops, produces, and distributes immunologic reagents optimized for use in NHP research, including antibodies for NHP in vitro immunodiagnostics, and primatized immuno-modulating or immuno-depleting recombinant antibodies and fusion proteins for in vivo administration. These reagents have been valuable in elucidating the immunologic mechanisms responsible for transplant rejection and tolerance, and for protection against infectious disease. Several antibodies have been developed as proof-of-concept in NHPs for new therapeutic approaches in human transplantation medicine. Table 2
© 2019 Elsevier Inc.